ArticlePediatric nephrology (Berlin, Germany)2006
Rituximab therapy for steroid-dependent minimal change nephrotic syndrome.
Article in Pediatric nephrology (Berlin, Germany), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Prognostic factors of severe pneumonia in patients treated with rituximab in the intensive care unit.The Journal of international medical research · 2022Pooled it
- Rituximab shows no effect on remission in patients with refractory nephrotic syndrome: A MOOSE-compliant meta-analysis.Medicine · 2016Pooled it
- Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea.Medicine · 2018Trial
- Rituximab efficiency in children with steroid-dependent nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2010Trial
- Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children.Pediatric nephrology (Berlin, Germany) · 2009Trial
- Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases.Pediatric nephrology (Berlin, Germany) · 2008Trial
- Rituximab for refractory minimal change disease: Long-term outcomes in the remission maintenance phase.Medicine · 2025Observational
- Steroid-resistant nephrotic syndrome as paraneoplastic syndrome of Waldenström macroglobulinemia: a case report.CEN case reports · 2025Article
- Emerging role of Rituximab in adult minimal change disease: a narrative review of clinical evidence, biomarkers and future perspectives.BMC nephrology · 2025Review
- "Idiopathic" minimal change nephrotic syndrome: a podocyte mystery nears the end.American journal of physiology. Renal physiology · 2023Review
- Using real-world data to inform dosing strategies of rituximab for pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome: a prospective pharmacokinetic-pharmacodynamic study.Frontiers in pharmacology · 2023Article
- Efficacy of repeat-dose rituximab maintenance therapy for minimal change disease in adults.Clinical and experimental nephrology · 2020Article
- Outcomes of Older Patients (≥60 years) with New-Onset Idiopathic Nephrotic Syndrome Receiving Immunosuppressive Regimen: A Multicentre Study of 116 Patients.Journal of clinical medicine · 2019Article
- Rituximab Use in the Management of Childhood Nephrotic Syndrome.Frontiers in pediatrics · 2019Review
- Concurrent isolated IgG2-positive membranous nephropathy and malignant B-cell lymphoma.CEN case reports · 2018Article
- Rituximab in steroid-sensitive nephrotic syndrome: lessons from clinical trials.Pediatric nephrology (Berlin, Germany) · 2018Review
- Minimal change disease with maximum immunosuppression: successful treatment of steroid-dependent minimal change disease with rituximab.BMJ case reports · 2018Article
- Available and incoming therapies for idiopathic focal and segmental glomerulosclerosis in adults.Journal of nephrology · 2018Review
- Cost-Effectiveness of Administering Rituximab for Steroid-Dependent Nephrotic Syndrome and Frequently Relapsing Nephrotic Syndrome: A Preliminary Study in Japan.Scientific reports · 2017Article
- Rituximab for nephrotic syndrome in children.Clinical and experimental nephrology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present a patient with steroid-sensitive but high-dose steroid-dependent nephrotic syndrome who was treated with rituximab. For 9 months following therapy she had undetectable CD19 cells in the peripheral circulation. She remained in remission during this period even though therapy was reduced to low-dose, alternate day prednisolone only. After 9 months, CD19 cells were once again detectable. Shortly after CD19 cells became detectable again she relapsed. We conclude that B-lymphocytes play a central role in the pathogenesis of idiopathic minimal change nephrotic syndrome (MCNS) and that rituximab may have a useful role in the management of steroid-dependent patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.